Six biotechnology stocks are moving up in their overall rating this week, according to the Portfolio Grader database. Every one of these is graded an “A” (“strong buy”) or “B” overall (“buy”).
This week, OvaScience, Inc. (OVAS) is making solid headway. The company’s rating improves to an A (“strong buy”) from last week’s B (“buy”) rating. Shares of the stock have been trading at an exceptionally rapid pace, up twofold from the week prior. For more information, get Portfolio Grader’s complete analysis of OVAS stock.
ZIOPHARM Oncology, Inc. (ZIOP) is seeing ratings go up from a B last week to an A this week. ZIOPHARM Oncology is a biopharmaceutical company that engages in the development and commercialization of small molecule and synthetic biology approaches to cancer therapies in the United States. For more information, get Portfolio Grader’s complete analysis of ZIOP stock.
This week, Receptos, Inc. (RCPT) pushes up from a B to an A rating. For more information, get Portfolio Grader’s complete analysis of RCPT stock.
Ambit Biosciences Corp. (AMBI) is making progress this week as its rating of C (“hold”) from last week increases to a B (“buy”) rating this week. For more information, get Portfolio Grader’s complete analysis of AMBI stock.
Intrexon Corporation (XON) shows solid improvement this week. The company’s rating rises from a C to a B. Shares of the stock have been changing hands at an unusually rapid pace, three times the rate of the week prior. For more information, get Portfolio Grader’s complete analysis of XON stock.
Fibrocell Science, Inc. (FCSC) earns a B this week, jumping up from last week’s grade of C. Shares of the stock have been trading at an exceptionally rapid pace, up 4470.3% from the week prior. For more information, get Portfolio Grader’s complete analysis of FCSC stock.
Louis Navellier’s proprietary Portfolio Grader stock ranking system assesses roughly 5,000 companies every week based on a number of fundamental and quantitative measures. Stocks are given a letter grade based on their results — with A being “strong buy,” and F being “strong sell.” Explore the tool here.
